SCHEMBL4179368

SCHEMBL4179368

O=C(CC1CCCCC1)NO

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.63
HPGD P15428 3/20 0.63
EPHX1 P07099 1/20 0.63
RAB9A P51151 4/20 0.52
NPC1 O15118 3/20 0.52
EPHX2 P34913 3/20 0.52
HDAC8 Q9BY41 2/20 0.47
HDAC6 Q9UBN7 2/20 0.47
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC9 Q9UKV0 1/20 0.47
HDAC5 Q9UQL6 1/20 0.47
AAK1 Q2M2I8 1/20 0.46
POLB P06746 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4179001 1.00 KMT2A (0.63) KMT2AHPGDEPHX1RAB9ANPC1
SCHEMBL13043831 0.98 KMT2A (0.59) KMT2AHPGDEPHX1RAB9ANPC1
Propionamide SCHEMBL6017481 0.87 KMT2A (0.50) KMT2AHPGDEPHX1RAB9ANPC1
SCHEMBL11356392 0.86 HPGD (0.53) KMT2AHPGDEPHX1RAB9ANPC1
SCHEMBL18090914 0.84 KMT2A (0.61) KMT2AHPGDEPHX1RAB9ANPC1
SCHEMBL26332838 0.81 KMT2A (0.57) KMT2AHPGDEPHX1RAB9ANPC1
SCHEMBL24235893 0.79 KMT2A (0.61) KMT2AHPGDEPHX1RAB9ANPC1
SCHEMBL14456383 0.79 KMT2A (0.61) KMT2AHPGDEPHX1RAB9ANPC1
SCHEMBL14606389 0.79 KMT2A (0.61) KMT2AHPGDEPHX1RAB9ANPC1
SCHEMBL1779033 0.79 KMT2A (0.61) KMT2AHPGDEPHX1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111285785-B Synthetic method of hydroximic acid collecting agent 广东省资源综合利用研究所 2023-04-07 CN disclosed
CN-108929246-B Method for preparing hydroximic acid derivatives by solid-state method 湖南中医药大学 2021-07-02 CN disclosed
CN-111285785-A Synthetic method of hydroximic acid collecting agent 广东省资源综合利用研究所 2020-06-16 CN disclosed
EP-1727516-B1 COMPOSITION COMPRISING AN HDAC INHIBITOR IN COMBINATION WITH A RETINOID DSM IP ASSETS BV (NL) 2014-05-14 EP disclosed
US-8227516-B2 Compounds as histone deacetylase inhibitors 4SC DISCOVERY GMBH (DE) 2012-07-24 US disclosed
US-8227516-B2 Compounds as histone deacetylase inhibitors 4SC DISCOVERY GMBH (DE) 2012-07-24 US disclosed
US-8227516-B2 Compounds as histone deacetylase inhibitors 4SC DISCOVERY GMBH (DE) 2012-07-24 US disclosed
CN-1933802-B Composition comprising an hdac inhibitor in combination with a retinoid DSM IP ASSETS BV 2011-07-06 CN disclosed
US-20090088478-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS 4SC DISCOVERY GMBH (DE) 2009-04-02 US disclosed
US-20090088478-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS 4SC DISCOVERY GMBH (DE) 2009-04-02 US disclosed
CN-1933802-A Composition comprising an hdac inhibitor in combination with a retinoid DSM IP ASSETS BV (NL) 2007-03-21 CN disclosed
US-20050176686-A1 Novel compounds as histone deacetylase inhibitors 4SC AG (DE) 2005-08-11 US disclosed
EP-1523470-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2005-04-20 EP disclosed
CN-1183107-C Alkynyl containing hydroxamic acid compounds as TACE inhibitors ���Ͽع����޹�˾ 2005-01-05 CN disclosed
WO-2004009536-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2004-01-29 WO disclosed
WO-2004009536-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2004-01-29 WO disclosed
EP-1299377-A2 SPLA2 INHIBITORS ELI LILLY AND COMPANY (US) 2003-04-09 EP disclosed
CN-1337945-A Alkynyl containing hydroxamic acid compounds as TACE inhibitors AMERICAN CYANAMID CO (US) 2002-02-27 CN disclosed
WO-2002000641-A2 SPLA2 INHIBITORS ELI LILLY AND COMPANY (US) 2002-01-03 WO disclosed
US-4611053-A METAL CHELATE COMPOUNDS, DETOXIFICATION OF BLOOD SASA MICHIYUKI MITCH 1986-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176686-A1 Novel compounds as histone deacetylase inhibitors HDAC3, HDAC1, HDAC2 KMT2A 95/4885HPGD 1495/4885EPHX1 2932/4885
US-20090088478-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC11, HDAC5 KMT2A 99/4885HPGD 556/4885EPHX1 3499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.